238,565 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Acquired by Wasatch Advisors LP

Wasatch Advisors LP bought a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 238,565 shares of the company's stock, valued at approximately $1,431,000. Wasatch Advisors LP owned approximately 0.92% of Eton Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Westside Investment Management Inc. increased its holdings in shares of Eton Pharmaceuticals by 2.0% during the 2nd quarter. Westside Investment Management Inc. now owns 585,400 shares of the company's stock worth $1,926,000 after acquiring an additional 11,440 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Eton Pharmaceuticals by 86.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company's stock valued at $390,000 after purchasing an additional 30,167 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Eton Pharmaceuticals by 63.8% in the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company's stock valued at $350,000 after purchasing an additional 41,469 shares during the period. Stonepine Capital Management LLC bought a new position in shares of Eton Pharmaceuticals in the second quarter valued at about $362,000. Finally, Thompson Siegel & Walmsley LLC acquired a new stake in shares of Eton Pharmaceuticals during the 2nd quarter worth about $420,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, major shareholder Opaleye Management Inc. bought 57,500 shares of the business's stock in a transaction dated Tuesday, September 10th. The stock was purchased at an average cost of $4.65 per share, for a total transaction of $267,375.00. Following the transaction, the insider now owns 2,660,000 shares in the company, valued at $12,369,000. The trade was a 2.21 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have acquired a total of 85,600 shares of company stock worth $462,674 in the last quarter. Corporate insiders own 14.89% of the company's stock.

Eton Pharmaceuticals Stock Down 7.9 %

Shares of Eton Pharmaceuticals stock traded down $1.07 during trading on Monday, reaching $12.46. The company's stock had a trading volume of 518,036 shares, compared to its average volume of 104,731. Eton Pharmaceuticals, Inc. has a 52 week low of $3.03 and a 52 week high of $13.98. The firm has a market cap of $321.97 million, a PE ratio of -57.14 and a beta of 1.25. The business's 50-day moving average price is $8.67 and its 200-day moving average price is $5.56.

Wall Street Analyst Weigh In

A number of research analysts recently commented on ETON shares. Craig Hallum upped their price target on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a "buy" rating in a research note on Monday, October 28th. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price (up previously from $11.00) on shares of Eton Pharmaceuticals in a research report on Tuesday, November 26th.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.